Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...

Urinary Bladder

Urinary Bladder

The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...

The Micturition Reflex

The Micturition Reflex

Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating urine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Use of synthetic slings and mesh implants in the treatment of female stress urinary incontinence and prolapse : Statement of the Working Group on Urological Functional Diagnostics and Female Urology of the Academy of the German Society of Urology].

Der Urologe. Ausg. A·2019

Same author

[Not Available].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2015

Same author

[Not Available].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2015

Same author

Results of a BoNT/A antibody study in children and adolescents after onabotulinumtoxin A (Botox®) detrusor injection.

Urologia internationalis·2011

Same author

[Botulinum toxin (BoNT) : Short form of a European consensus panel report regarding recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions].

Der Urologe. Ausg. A·2009

Same author

[Complete resection of urothelial cancer metastases with curative intent].

Der Urologe. Ausg. A·2009

Same journal

Der Urologe. Ausg. A·2022

Same journal

Der Urologe. Ausg. A·2022

Same journal

Der Urologe. Ausg. A·2022

Same journal

Der Urologe. Ausg. A·2022

Same journal

Der Urologe. Ausg. A·2022

Same journal

Der Urologe. Ausg. A·2022

See all related articles

Search research articles

Related Experiment Video

Updated: May 25, 2026

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

[Botulinum toxin for neurogenic bladder dysfunction].

H Schulte-Baukloh¹

¹Abteilung für Urologie, St. Hedwig Kliniken, Große Hamburger Straße 5-11, 10115 Berlin, Deutschland. H.Schulte-Baukloh@alexius.de

Der Urologe. Ausg. A

|January 25, 2012

Summary

This summary is machine-generated.

Botulinum neurotoxin A (BoNT/A) injections effectively treat neurogenic bladder disorders by improving symptoms and bladder function. Repeated treatments are safe and necessary as effectiveness diminishes after approximately nine months.

More Related Videos

A Decentralized (Ex Vivo) Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling

A Decentralized (Ex Vivo) Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling

Published on: November 28, 2019

Related Experiment Videos

Last Updated: May 25, 2026

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

A Decentralized (Ex Vivo) Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling

A Decentralized (Ex Vivo) Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling

Published on: November 28, 2019

Area of Science:

Urology
Neurology

Context:

Botulinum neurotoxin (BoNT) has gained prominence in treating neurogenic bladder dysfunction over the past 12 years.
It offers an alternative to conservative therapies and reduces the need for surgical interventions.
Botulinum neurotoxin A (BoNT/A) has been approved for neurogenic bladder disorders since September 2011.

Purpose:

To summarize key findings on the practical application of BoNT/A for neurogenic bladder disorders.
To review the efficacy and safety of BoNT/A in urological practice.

Summary:

Botulinum neurotoxin A (BoNT/A) is the most utilized subtype, demonstrating significant efficacy via detrusor injections.
Full therapeutic effects manifest within approximately seven days.
Improvements include enhanced bladder capacity, reduced maximum detrusor pressure, and better subjective parameters like reduced urination frequency, incontinence, and improved quality of life.
Effectiveness wanes after about nine months, necessitating repeated injections, which have proven effective.
Systemic side effects are rare; however, increased residual urine leading to urinary retention is a notable urologic side effect.

Impact:

BoNT/A injections offer a minimally invasive treatment option for neurogenic bladder dysfunction.
The treatment improves patient quality of life and reduces reliance on more invasive procedures.
Understanding the duration of effect and potential side effects is crucial for patient management and optimizing treatment outcomes.